key: cord-0860728-uaozfjia authors: PAGANO, Livio; SALMANTON-GARCÍA, Jon; MARCHESI, Francesco; LÓPEZ-GARCÍA, Alberto; LAMURE, Sylvain; ITRI, Federico; GOMES-SILVA, Maria; DRAGONETTI, Giulia; FALCES-ROMERO, Iker; VAN DOESUM, Jaap; SILI, Uluhan; LABRADOR, Jorge; CALBACHO, Maria; BILGIN, Yavuz M.; WEINBERGEROVÁ, Barbora; SERRANO, Laura; RIBERA-SANTA SUSANA, José-María; MALAK, Sandra; LOUREIRO-AMIGO, José; GLENTHØJ, Andreas; CÓRDOBA-MASCUÑANO, Raúl; NUNES-RODRIGUES, Raquel; GONZÁLEZ-LÓPEZ, Tomás-José; KARLSSON, Linda Katharina; JIMÉNEZ-LORENZO, María-Josefa; HERNÁNDEZ-RIVAS, José-Ángel; JAKSIC, Ozren; RÁČIL, Zdeněk; BUSCA, Alessandro; CORRADINI, Paolo; HOENIGL, Martin; KLIMKO, Nikolai; KÖHLER, Philipp; PAGLIUCA, Antonio; PASSAMONTI, Francesco; CORNELY, Oliver A. title: COVID-19 in vaccinated adult patients with hematological malignancies. Preliminary results from EPICOVIDEHA date: 2021-11-10 journal: Blood DOI: 10.1182/blood.2021014124 sha: 9a3d2387006372eb25627dffc17ae332d26c9765 doc_id: 860728 cord_uid: uaozfjia nan . After a follow-up of 30 days post COVID-19 diagnosis, the overall mortality 183 rate was 12.4% (N=14). COVID-19 was the main or a secondary cause of death for all but one 184 patients; interestingly, we did not observe any statistical difference in terms of mortality between 185 partially or fully vaccinated patients (15.4% vs 11.5%; P=0.734) and between patients achieving a 186 serological response to vaccine vs non responders (13.3% vs 15.6%; P=1). In addition, we did not 187 find any significant differences in terms of age or comorbidities comparing responder vs non 188 responder patients. Moreover, our multivariable analysis showed that the only factor independently 189 related to the risk of death in our cohort of vaccinated patients was the age (P=0.035; HR 1.053, 190 95%CI: 1.004-1.105) (Supplemental Table 2 This has also been observed for other vaccinations (e.g., influenza). [15] [16] Our results suggest that 202 the low serologic response rate to anti-SARS-CoV-2 vaccines in patients with HM may translate to 203 higher rates of infections. This has previously been described following monoclonal antibody 204 treatment. [17] [18] [19] [20] [21] [22] [23] Unfortunately, only little data is available on the genomic characterization of the 205 virus, we expect having a greater proportion of genotyping cases while continuing the survey. 206 Given policies that differ between sites, post-vaccination serology results were available in only 207 about 35% of patients and of those about two thirds were serologically non responders. It should 208 be taken into account that the methods differ from a center to anotherone, even though our attempt 209 of reducing inter-laboratory variation by referring to the WHO standardized method 210 (https://www.who.int/news-room/feature-stories/detail/standardization-of-vaccines-for-coronavirus-211 disease-covid-19). Importantly, the overall mortality observed in our patients, although lower than 212 in the pre-vaccination period (~31%), remained high (12.4%). This percentage, on one hand 213 remains quite worrying for hematologists, but on the other hand should be interpretated as a 214 significant achievement following the spread of vaccination programs around the world. The 215 hospitalization and mortality are still higher than the one observed in the fully vaccinated general 216 population where the hospitalization rates of 2-3% have been reported. 12, 13, 24, 25 Our study reports 217 preliminary observations and the low number of vaccinated patients is the main weakness, for now 218 limiting the possibility to define the real incidence of breaktrough COVID-19 in HM. 219 Recruitment to this survey continues and larger numbers of cases will enable us to draw 220 more conclusions in order to develop strategies to prevent severe COVID-19 in this frail population. 221 Informed consent was collected as applicable. All the authors have no disclosures to declare for this submitted paper. 246 Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub COVID-19 and stem cell transplantation; results from an EBMT and GETH multicentre prospective study Online ahead of print Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study EPICOVIDEHA: a ready-to use platform for epidemiological studies in hematological patients with COVID-19 COVID-19 Infection in Adult Patients with Hematological Malignancies: A European Hematology Association Survey (EPICOVIDEHA) Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine Preliminary recommendations of the NCCN Vaccination Advisory Committee Living guidance World Health Organization Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention Covid-19 Breakthrough Infections in Vaccinated Health Care Workers Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings Hospitalisation among vaccine breakthrough COVID-19 infections Online ahead of print Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: a randomised study 2017 ECIL 7 vaccine guidelines. ECIL vaccine group Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia Fifth-week-immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single Institution BNT162b2 vaccine is significantly less effective in patients with hematologic malignancies Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment Effectiveness of SARS-CoV-2 mRNA Vaccines for Preventing Covid-19 Hospitalizations in the United States SARS-CoV-2 Infections and Hospitalizations Among Persons Aged ≥16 Years, by Vaccination Status